The Japanese Respiratory Society Noninvasive Positive Pressure Ventilation (NPPV) Guidelines (second revised edition)  by Akashiba, Tsuneto et al.
Contents lists available at ScienceDirectRespiratory Investigation
r e s p i r a t o r y i n v e s t i g a t i o n 5 5 ( 2 0 1 7 ) 8 3 – 9 2http://dx.doi.org/10
2212-5345/& 2015 Tjournal homepage: www.elsevier.com/locate/resinvGuidelineThe Japanese Respiratory Society Noninvasive
Positive Pressure Ventilation (NPPV) Guidelines
(second revised edition)Tsuneto Akashibaa,1, Yuka Ishikawab,1, Hideki Ishiharac,1,
Hideaki Imanakad,1, Motoharu Ohie,1, Ryoichi Ochiaif,1, Takatoshi Kasaig,1,
Kentaro Kimurah,1, Yasuhiro Kondohi,1, Shigeru Sakuraij,1, Nobuaki Shimek,1,
Masayuki Suzukawal,1, Misa Takegamim,1, Shinhiro Takedan,1,
Sadatomo Tasakao,1, Hiroyuki Taniguchii,1, Naohiko Chohnabayaship,1,
Kazuo Chinq,n,1, Tomomasa Tsuboir,1, Keisuke Tomiis,1, Koji Naruit,1,
Nobuyuki Hasegawau,1, Ryuichi Hasegawav,1, Yoshihito Ujikew,2,3,
Keishi Kubox,2,4, Yoshinori Hasegaway,2,4, Shin-ichi Momomuraz,2,5,
Yoshitsugu Yamadaaa,2,6, Masahiro Yoshidaab,2,7, Yukie Takekawaac,8,
Ryo Tachikawaad,8, Satoshi Hamadaad,8, Kimihiko Murasead,8
aDivision of Sleep and Respiratory Medicine, Nihon University School of Medicine
bDepartment of Pediatrics, National Hospital Organization Yakumo National Hospital
cDepartment of Respiratory Medicine, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
dDepartment of ER/Disaster Medical Care, Tokushima University Hospital
eRespiratory and Sleep Medicine Center, Osaka Kaisei Hospital
fAnesthesiology and Intensive Care Medicine of Toho University Omori Medical Center
gCardio-Respiratory Sleep Medicine, Department of Cardiovascular Medicine, Juntendo University, Graduate School of
Medicine
hFormer Director of Osaka Anti-tuberculosis Association, Osaka Hospital
iDepartment of Respiratory Medicine and Allergy, Tosei General Hospital
jDivision of Behavioral Sleep Medicine, School of Medicine, Iwate Medical University
kEmergency and Critical Care Medicine, National Hospital Organization Kyoto Medical Center
lEmergency Medicine, Jichi Medical University
mDepartment of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center
nDepartment of Intensive Care Medicine, Nippon Medical School Hospital
oDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine
pDivision of Pulmonary Medicine in Thoracic Center, St. Luke’s International Hospital
qDepartment of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University
rDepartment of Respiratory Medicine, National Hospital Organization Minami-Kyoto Hospital
sDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital
tThe Department of Sleep and Respiratory Medicine, Toranomon Hospital
uEmergency and Critical Care Center, Nasu Red Cross Hospital
vDepartment of Emergency and Critical Care Med, Mito Clinical Education and Training Center, Tsukuba University
Hospital / Mito Kyodo General Hospital.1016/j.resinv.2015.11.007
he Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
r e s p i r a t o r y i n v e s t i g a t i o n 5 5 ( 2 0 1 7 ) 8 3 – 9 284wDepartment of Emergency and Critical Care Medicine, Okayama University Graduate School of Medicine, Dentistry and
Pharmaceutical Sciences
xNagano Prefectural Hospital Organization
yDivision of Respiratory Medicine, Nagoya University Graduate School of Medicine
zSaitama Medical Center, Jichi Medical University
aaDepartment of Anesthesiology, Graduate School of Medicine, The University of Tokyo
abDepartment of Hemodialysis and Surgery, Chemotherapy Research Institute, Kaken Hospital
acCertiﬁed Nurse Specialist for Chronic Care Nursing, Osaka Prefectural Medical Center for Respiratory and Allergic
Diseases
adDepartment of Respiratory Medicine, Graduate School of Medicine, Kyoto UniversityRemarks regarding the publication of an abridged English
edition of the NPPV Guidelines (second revised edition) by the
Japanese Respiratory Society
After publication of the Japanese edition of the NPPV
Guidelines (second revised edition) by the Japanese Respira-
tory Society, an abridged English edition of the Guidelines
was planned and has now been published. The aim of
publishing the abridged English edition—which consists of
clinical questions (CQ), answers, and recommendations for
speciﬁc NPPV interventions—was to obtain opinions from
specialists in the ﬁeld outside Japan.
Regarding the Publication of the Second Revised Edition
1. Developments after publication of the ﬁrst edition of
the NPPV Guidelines warranted publication of a second,
revised edition
New developments in the approximately eight years since
the publication of the ﬁrst edition of the Noninvasive Positive
Pressure Ventilation (NPPV) Guidelines have warranted pub-
lication of a second, revised edition. Since NPPV for home use
was covered by health insurance in 1998, the number of
patients using NPPV therapy at home has rapidly increased　
in Japan. Although NPPV guidelines for management of
patients with acute respiratory failure (including some
patients with chronic respiratory failure) had already existed,
no wide-ranging guidelines that also included chronic-stage
patients had been developed. In addition, while health
insurance coverage for artiﬁcial ventilation administered at
home was only intended for patients with stable medical
conditions whom the treating physicians considered to be
suited for mechanical ventilation at home (except for patients
with sleep apnea), no speciﬁc criteria had been established.
For these reasons, the ﬁrst edition of the Guidelines played a
role in increasing the understanding and dissemination of
this treatment method in Japan.
Since the publication of the ﬁrst edition, the scope of patients
indicated for NPPV therapy has expanded, and new equipment
and techniques, such as adaptive servo ventilation (ASV), havenCorresponding author. Tel.: þ81 75 751 3852; fax: þ81 75 751 3854.
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associated pneumonia and NPPV and issues associated with
the use of NPPV during major disasters required consideration.
Thus, the second edition of the NPPV Guidelines addressed
these new changes and issues related to NPPV therapy.
2. Purpose and preparation of the Guidelines
a. Purpose
The ﬁrst edition of the NPPV Guidelines had two main
purposes: to disseminate information regarding new technolo-
gies and to introduce current evidence of the efﬁcacy of NPPV
therapy. These two items were also the main focus of the
second edition: although seven years have passed since the
publication of the ﬁrst edition and NPPV is increasingly used in
respiratory care, NPPV is still a relatively new treatment
method. Therefore, the main focus of the second edition of
the Guidelines was to improve comprehension of the newest
evidence regarding the effectiveness of NPPV therapy. In addi-
tion, the new Guidelines also provide a general overview of
NPPV therapy and describe speciﬁc interventions.
b. Who should use these Guidelines
The Guidelines are intended to be used by physicians and
other medical team members, as these comprehensive med-
ical teams typically provide respiratory care. Moreover, in
order to address recent changes in NPPV therapy, sections
on NPPV systems, use of sedative agents, management during
natural disasters, and infection control were added to the
general overview. In addition, sections on the use of NPPV
during the perioperative period, in patients in the terminal
phases of disease, do-not-intubate patients or those with
malignant tumors, elderly patients, and children, as well as
sections on rehabilitation and hospital education were added
to the descriptions of speciﬁc interventions.
c. Patients targeted by the Guidelines
The Guidelines apply to patients with acute or chronic
respiratory failure who require NPPV therapy. In the Guide-
lines, patients with stable medical conditions (excluding
sleep apnea) whom the attending physicians considered toare Medicine.
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eligible for NPPV therapy through their health insurances
were set as the standard.
d. How the Guidelines were prepared
The items newly added to the second edition were the
result of literature searches for articles related to NPPV
published until December 2012; the items included in the
ﬁrst edition were obtained from literature searches of pri-
marily the PubMed and Igaku Chuo Zasshi literature data-
bases for articles published after the release of the ﬁrst
edition of the Guidelines. More recent literature was also
included when warranted. The draft guidelines were peer
reviewed by at least two committee members and were also
checked for errors and omissions regarding the included
literature. In addition to the literature cited in the draft
guidelines, peer-reviewed Japanese reports related to NPPV
therapy deemed relevant by members of the committee are
listed at the end of the relevant chapters under the heading
“Japanese reports on NPPV therapy.”
Regarding the costs of NPPV therapy, important notes
regarding the coverage of NPPV therapy by health insurance
are described in each section of the Guidelines.
Although non-invasive ventilation includes both continuous
positive airway pressure (CPAP) and NPPV, identical to the ﬁrst
edition, the second edition of the Guidelines is entitled “Non-
invasive Positive Pressure Ventilation (NPPV) Guidelines.”
Levels of evidence and grades of recommendation were
determined based on the assessment method used by the
Medical Information Network Distribution Service (MINDS)
(please refer to the “Description of evidence [EBM]” below).
Levels of evidence and grades of recommendation are
described for each particular intervention. Notably, the level
of evidence is only given in the general overview if it could be
accurately assessed based on information provided in the
literature.
After completion, the ﬁrst draft of the guidelines was
posted on the Japanese Respiratory Society (JRS) homepage
and amended and revised based on comments and feedback
from JRS members and other professionals.
e. Measures taken to promote the use of these Guidelines
To help ensure the reliability of the Guidelines, the
abridged Japanese edition of the speciﬁc interventions
described in the Guidelines was posted on the JRS homepage
with the aim of receiving feedback from JRS members and the
public. The abridged English edition of the Guidelines is
published here in order to seek opinions of specialists in
the ﬁeld outside of Japan. It should be noted that levels of
evidence and grades of recommendation provided in the
Guidelines are the current levels; the content of the Guide-
lines might be revised based on the results of future studies.
f. Scheduled revision of the Guidelines
Principally, the Guidelines will be revised approximately
every ﬁve years. As described above, we hope that the second
edition of the Guidelines will be widely reviewed by specia-
lists in the ﬁeld worldwide. Furthermore, together with the
JRS Guidelines Enforcement and Administration Committee,
we will continue to review the content of international
guidelines and current trends related to NPPV therapy, and
will also monitor revisions made to the Japanese healthinsurance system concerning the coverage provided for NPPV
therapy.
g. Precautions regarding the use of NPPV
As mechanical ventilation is often an essential element of
patient support, medical accidents are more likely to occur in
care that requires its use. Although it may be difﬁcult, it is
necessary to conﬁrm the will of the patient regarding treat-
ment containing respiratory management at the end stage of
disease. Moreover, the conditions under which mechanical
ventilation can be discontinued have not yet received sufﬁ-
cient social consensus. Although patients can be easily
connected to and removed from NPPV, this treatment
method also involves various uncertainties and may be
associated with more problems than invasive mechanical
ventilation. Therefore, before initiating NPPV therapy, the
patient and the patient’s family should be sufﬁciently
informed about this treatment method, and the will of the
patient and their family to conduct NPPV must be conﬁrmed.
In addition, attention should be paid to such issues as
treatment policy and risk management. In the Guidelines,
particularly in the general overview, implementation of NPPV
in patients with acute or chronic respiratory failure is
described in detail, in addition to the ﬁnancial and side
effects of NPPV therapy and their countermeasures.
3. Composition of the committee members
The committee that prepared the Guidelines was com-
prised of a broad range of health professionals from various
ﬁelds, and included not only physicians working in ﬁelds that
involve the use of NPPV, but also nurses and specialists in the
ﬁeld of epidemiology.
The diagnosis and treatment departments that frequently
use NPPV include respiratory medicine and emergency
departments and intensive care units (ICUs). Therefore, in
addition to doctors specialized in respiratory medicine, doc-
tors working in anesthesiology, emergency, and ICU depart-
ments were asked to join an external evaluation board.
Moreover, because the use of ASV (a form of NPPV therapy)
has recently increased in the ﬁeld of cardiovascular medicine,
we also asked doctors working in this ﬁeld to join the external
evaluation board. The Guidelines were also evaluated by the
board of directors of the JRS and the Guidelines Enforcement
and Administration Committee; the results of the evaluation
are also reﬂected in the Guidelines.
4. Conﬂicts of interest
The second edition of the NPPV Guidelines was prepared
with two aims: dissemination of new technologies and
introduction of current evidence of the effectiveness of
NPPV. The content of the Guidelines is based on scientiﬁc
evidence and does not underlie the interests of speciﬁc
organizations or promote speciﬁc products or technologies.
Moreover, the preparation of the Guidelines was fully
funded by the JRS, and no ﬁnancial support was received
from any other organizations or companies. All potential
conﬂicts of interests for JRS members involved in the pre-
paration of the Guidelines are disclosed below, according to
the provisions of the JRS.
● Conﬂict of interest (COI)
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manage and oversee potential COIs based on common COI
guidelines and detailed regulations that were formulated in
collaboration with societies related to internal medicine;
these guidelines and regulations posted on the JRS
homepage.
COI-related matters for committee members who helped
to prepare the second edition of the NPPV Guidelines include:
1) Receipt of research grants and other funding
Company names: Teijin Home Healthcare Ltd.; Teijin
Pharma, Ltd.; Philips Respironics GK; and Fukuda Denshi
Co., Ltd.
2) Acceptance of payment of fees for lectures or
manuscripts, etc.
Does not apply
3) Personal income of committee members resulting from the
preparation of the Guidelines
No committee members received any payment for the
preparation of the Guidelines that falls under the disclosure
standards of the JRS
● Handling of COIs
1) To avoid bias, we established a committee that included
specialists from other professions and ﬁelds.
2) Recommendations were determined by consensus deci-
sion-making among all members.
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Description of evidence (evidence-based medicine, EBM)
1) Levels of evidence and grades of recommendation were
determined based on the assessment method used by the
Medical Information Network Distribution Service (MINDS), as
described below for each particular intervention. The level of
evidence and grade of recommendation are included in the
general overview only if they could be accurately assessedfrom information available in the literature.
Level of evidenceI Systematic review, meta-analysis
II One or more randomized controlled trials
III Non-randomized controlled trials
IV Analytic epidemiological studies (based on cohort and
case-control studies)
V Descriptive studies (based on case reports and case
series)
VI Opinion of an expert committee and individual experts
that is not based on patient dataGrades of recommendationLevel A Strongly
recommen-
dedStrong evidence of effective-
ness, and substantial clinical
beneﬁt can be expectedLevel B Recommen-
dedModerate evidence of effective-
ness, or strong evidence,
but only minimal clinical effec-
tivenessLevel C1 Only little
scientiﬁc evi-
dence, but its
implementa-
tion is an
optionThere is a possibility that its
implementation will be
effectiveLevel C2 Cannot be
recommen-
ded due to a
lack of sufﬁ-
cient
evidenceNot sufﬁcient evidence to sup-
port or deny the effective-
ness scientiﬁcLevel D Not recom-
mendedEvidence that denies theeffec-
tiveness (or indi`cates that its
implementation is harmful for
the
patient)2) The search period for the literature used for the evaluation
was as follows
● Items from the ﬁrst edition: From the time when the
items were ﬁrst established and after publication of the ﬁrst
edition, to December 2012.
● New items: From the time that the reports were released
until December 2012
Literature searches were performed to identify articles
related to NPPV published until December 2012 that were
added to the second edition; similar to the process for items
included in the ﬁrst edition, literature searches for articles
published after the release of the ﬁrst edition of the Guide-
lines used primarily the PubMed and Igaku Chuo Zasshi
literature databases. More recent literature was also included
when warranted. The draft guidelines were peer reviewed by
at least two committee members and were also checked for
errors and omissions regarding the included literature. In
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reviewed Japanese reports related to NPPV therapy that
members of the committee deemed relevant are listed at
the end of the relevant chapters under the heading “Japanese
reports on NPPV therapy.”
Relevant literature published while the Guidelines were
being prepared is indicated at the end of each chapter under
the heading “Relevant literature published after the search
period.” Furthermore, as a general rule, the grades of recom-
mendation were determined based on research papers pub-
lished during the search period.
3) Selection criteria for determining the level of evidence
We adopted selection criteria that placed a higher priority
on studies with a high level of evidence. We searched both
Japanese and English literature. We did not adopt selection
criteria from animal studies or genetic research.
4) Determination of grades of recommendation
The recommendation grades were determined by consen-
sus among all committee members. In instances where a
consensus could not be reached, the grade was determined
by vote.
Non-invasive Positive Pressure Ventilation (NPPV) Guide-
lines (Second Revised Edition)
Table of Contents
General overview
1. Use of NPPV in acute respiratory failure
2. Use of NPPV in chronic respiratory failure
3. Mechanical ventilators and modes of NPPV
4. Initiation of NPPV for acute respiratory failure
5. Initiation of NPPV for chronic respiratory failure
6. Use of sedatives during NPPV
7. Factors correlated with NPPV outcomes and manage-
ment of commonly encountered difﬁculties
8. Medical safety
9. Disaster management
10. Infection control
11. Medical care following initiation of NPPV
Speciﬁc interventions
A. Acute respiratory failure
1. Exacerbation of chronic obstructive pulmonary
disease (COPD)
2. Asthma
3. Exacerbation of restrictive thoracic disease (RTD)
4. Interstitial pneumonia
5. Cardiogenic pulmonary edema
6. Thoracic injury
7. Use as a support method when weaning patients from
mechanical ventilation
8. Use during the perioperative period
9. Immunocompromised and immunosuppressed patients
with acute respiratory failure
10. Acute respiratory distress syndrome (ARDS) and
severe pneumonia11. Use in patients in the terminal phase of a disease,
patients with do-not-intubate (DNI) orders, patients with
malignant tumor, and elderly patients
12. Use in children
B. Chronic respiratory failure
1. Restrictive ventilatory defect
2. COPD (chronic stage)
3. Cheyne–Stokes respiration (CSR) in chronic heart
failure (CHF)
4. Obesity-hypoventilation syndrome
5. Neuromuscular disease
6. Use in children
7. Rehabilitation
Speciﬁc interventions
A: Acute respiratory failure
1. Exacerbation of chronic obstructive pulmonary disease
(COPD)
CQ1 Should NPPV be used for respiratory management of
patients with acute respiratory failure due to exacerbation
of COPD?
Answer: Among various indications for NPPV in patients
with acute respiratory failure, the most extensively studied is
exacerbation of COPD. The Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines recommend
NPPV as an effective treatment method to improve respira-
tory acidosis; reduce respiratory rate, the work of breathing,
and respiratory distress; reduce complications such as
ventilator-associated pneumonia; shorten the length of hos-
pitalization; and help avoid intubation, thus signiﬁcantly
improving survival rates. For its most effective use, it is
essential for NPPV therapy to be used only in patients
considered to be suitable candidates and with the appropriate
timing of initiation. It is also important that medical staff be
familiar with the use of NPPV.
Recommendation rating of NPPV for CQ1: NPPV should be
used for management of acute respiratory failure due to
exacerbation of COPD. [Level I evidence, Grade A reco-
mmendation]
2. Asthma
CQ2 Should NPPV be used for respiratory management of
asthmatic attacks?
Answer: Tracheal intubation and mechanical ventilation
are currently considered the ﬁrst-line treatment in patients
suffering asthmatic attacks. However, many reports suggest
that NPPV is effective for respiratory management of asth-
matic attacks, and use of NPPV in these patients has gradu-
ally increased in clinical practice. At facilities sufﬁciently
familiar with its use, NPPV in selected patients has various
advantages, including improved dyspnea and respiratory
function, avoidance of tracheal intubation, and decreased
length of hospitalization. However, because sudden-onset
asthma exacerbations can be life-threatening if intubation
is delayed, medical staff should not hesitate to switch from
NPPV therapy to respiratory management by tracheal intuba-
tion if signs of progressive exacerbation are observed.
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respiratory failure during asthmatic attacks, NPPV should not
be conducted on a day-to-day basis at facilities with limited
experience.
Recommendation rating of NPPV for CQ2: NPPV can be used
for management of acute respiratory failure during asthmatic
attacks. [Level II evidence, Grade C1 recommendation (Grade C2
recommendation at facilities with limited experience)]
3. Exacerbation of restrictive thoracic disease (RTD)
CQ3 Should NPPV be used for respiratory management of
an exacerbation of restrictive thoracic disease?
Answer: No conclusion has been reached concerning
the effectiveness of NPPV for management of acute
respiratory failure in patients with RTD, including pul-
monary tuberculosis sequelae, because there are few
documented critical care patients, such as ICU patients.
Based on the few reported cases of RTD in the United
States and Europe that used NPPV for management of
acute respiratory failure, intubation and invasive mechan-
ical ventilation can be avoided only in approximately 50%
of cases. However, in Japan, more favorable outcomes
have been reported for patients with RTD. Therefore, at
facilities familiar with its use, NPPV is strongly recom-
mended as ﬁrst-line treatment for respiratory manage-
ment of patients with acute RTD.
Recommendation rating of NPPV for CQ3: NPPV is recom-
mended as a ﬁrst-line treatment in patients with exacerba-
tion of RTD. [Level IV evidence, Grade A recommendation]
4. Interstitial pneumonia
CQ4 Should NPPV be used for the respiratory management
of patients with acute respiratory failure due to interstitial
pneumonia?
Answer: Patients with interstitial pneumonia and acute
respiratory failure treated by intubation and mechanical
ventilation have an increased risk of ventilator-associated
lung injury and pneumonia. Therefore, it is expected that
NPPV therapy, which precludes the use of intubation, will
lead to decreased rates of complications and mortality among
these patients. At present, there is not sufﬁcient evidence to
support the use of NPPV for patients with acute respiratory
failure due to interstitial pneumonia. However, because
intubation and mechanical ventilation are considered to have
poor prognosis, particularly in patients with acute respiratory
failure due to exacerbation of idiopathic pulmonary ﬁbrosis,
NPPV may be offered as a trial therapy for these patients after
obtaining informed consent.
Recommendation rating of NPPV for CQ4: NPPV can be
used for the management of acute respiratory failure in
patients with interstitial pneumonia. [Level IV evidence,
Grade C1 recommendation]
5. Cardiogenic pulmonary edema
CQ5 Should CPAP or bilevel PAP be used for mechan-
ical ventilation in patients with acute cardiogenic pulm-
onary edema?Answer: The results of numerous meta-analyses on the
clinical outcomes of NPPV in patients with acute cardiogenic
pulmonary edema have conﬁrmed its effectiveness. Com-
pared to oxygen therapy, CPAP signiﬁcantly reduces respira-
tory rates, increases the ratios of arterial oxygen partial
pressure to fractional inspired oxygen (P/F ratios), improves
hemodynamic status, and reduces rates of tracheal intuba-
tion and mortality. Notably, NPPV therapy was shown to
rapidly improve tachycardia. Bilevel PAP has been found to
have a similar effectiveness as CPAP, but has not been proven
to improve mortality. No differences in the incidence of
myocardial infarction have been detected between CPAP
and bilevel PAP. In addition, CPAP and bilevel PAP are also
effective treatment methods for management of acute pul-
monary edema associated with acute myocardial infarction,
with the exception of cardiogenic shock.
Recommendation rating of NPPV for CQ5: NPPV (particu-
larly CPAP) should be used as ﬁrst-line treatment in patients
with acute cardiogenic pulmonary edema. [Level I evidence,
Grade A recommendation]
6. Thoracic injury
CQ6 Should NPPV be used for respiratory management of
patients with acute respiratory failure due to thoracic injury?
Answer: One systematic review and three randomized
controlled trials have demonstrated the effectiveness of NPPV
for cases of thoracic injury, in addition to various reported
case series studies. However, all of the examined cases
differed with respect to the number and severity of injuries
in addition to thoracic injury. At facilities sufﬁciently familiar
with the use of NPPV and management of injuries and when
indicated, NPPV therapy may accelerate the improvement of
respiratory function while preventing complications, redu-
cing the requirement for intubation, and enabling earlier
intake of oral medication. However, patients should be
monitored for development or progression of pneumothorax
associated with positive pressure ventilation. At facilities
unfamiliar with its use for injury management, it is difﬁcult
to recommend the use of NPPV. The therapeutic effect of
NPPV should be evaluated between 30 and 60 minutes after
introducing the NPPV system to the patients, and if no
improvement is observed, the medical staff should not
hesitate to switch patients to tracheal intubation.
Recommendation rating of NPPV for CQ6: NPPV can be
used for patients with acute respiratory failure due to
thoracic injury. [Level II evidence, Grade C1 recommendation
(Grade B recommendation at experienced facilities)]
7. Use as a support method when weaning patients from
mechanical ventilation
CQ7 Is NPPV a useful support method when weaning a
patient from invasive mechanical ventilation?
Answer: The recommendation level of NPPV as a support
method when weaning a patient from invasive mechanical
ventilation, which involves tracheal intubation, differs
depending on underlying disease. According to a meta-
analysis, NPPV is a useful support method when weaning
patients with COPD exacerbation from invasive mechanical
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length of stay in the ICU and hospital, and duration of
mechanical ventilation. However, approximately 50% of the
data from these randomized controlled trials are not publicly
available, and the timing of initiating NPPV as a support
therapy when weaning a patient from mechanical ventilation
has not been deﬁned. Moreover, the majority of these studies
were comprised of COPD patients with exacerbations, and the
usefulness of NPPV as a support therapy when weaning
patients with other medical conditions from mechanical
ventilation is unknown.
Recommendation rating of NPPV for CQ7: NPPV is useful
when weaning patients with complications from COPD from
invasive mechanical ventilation. [Level I evidence, Grade B
recommendation]
8. Use during the perioperative period
CQ8 Is respiratory management by NPPV useful for pre-
vention and treatment of respiratory complications during
the perioperative period?
Answer: During the perioperative period, respiratory and
diaphragmatic functions are impaired due to anesthesia and
surgical stress; therefore, respiratory complications, includ-
ing pulmonary atelectasis, pneumonia, and hypoxemia, often
arise. Multiple randomized controlled trials have been con-
ducted on the prevention and treatment of respiratory
complications following abdominal, thoracic, or cardiovascu-
lar surgery, and have conﬁrmed that use of NPPV during the
perioperative period improves oxygenation and decreases
rates of reintubation and pneumonia after surgery. At facil-
ities familiar with its use, the use of NPPV for patients for
which it is indicated may facilitate improvement of respira-
tory function and reduce respiratory complications; however,
there remains insufﬁcient evidence for the efﬁcacy of NPPV in
such cases.
Recommendation rating of NPPV for CQ8: NPPV may be
useful for the prevention and treatment of respiratory com-
plications during the perioperative period. [Level II evidence,
Grade B recommendation]
9. Immunocompromised and immunosuppressed pati-
ents with acute respiratory failure
CQ9 Should NPPV be used for respiratory management of
immunodeﬁcient patients with acute respiratory failure?
Answer: Two randomized controlled trials and large-scale
retrospective studies have examined the usefulness of NPPV
intervention for management of acute respiratory failure in
patients immunosuppressed due to intensive chemotherapy
for treatment of hematological malignancy or solid tumor, or
patients immunosuppressed after bone marrow or organ
transplantation or steroid use. The use of NPPV prevented
patients from being switched to intubation with mechanical
ventilation; thus, the use of NPPV can be expected to reduce
the frequency of complications, including infections, and
improve the prognosis of these patients.
Recommendation rating of NPPV for CQ9: NPPV is recom-
mended as a ﬁrst-line treatment for the management of
immunodeﬁcient patients with acute respiratory failure.[Level II evidence, Grade A recommendation]
10. Acute respiratory distress syndrome (ARDS) and
severe pneumonia
CQ10 Should NPPV be used for respiratory management of
patients with ARDS?
CQ11 Should NPPV be used for management of patients
with severe pneumonia?
Answer: NPPV is reportedly effective for respiratory man-
agement of some patients with ARDS. In general, however,
these patients receive positive pressure ventilation with
tracheal intubation. According to the results of a meta-
analysis, NPPV therapy is not effective in approximately
50% of patients. Therefore, the use of NPPV in patients with
ARDS should be conducted with caution. In particular, intu-
bation should be considered for patients with poor systemic
condition and for those without improvement of the P/F ratio
1 h after initiation of NPPV.
In patients with severe pneumonia (excluding patients
with complications caused by immunodeﬁciency), the recom-
mendation level for NPPV therapy differs depending on the
underlying disease. The use of NPPV is recommended in
patients with COPD complicated by severe pneumonia
because NPPV shortens the length of stay in the ICU and
reduces intubation and mortality rates. However, there is no
evidence to support the use of NPPV for management of
severe pneumonia in patients without COPD as an underlying
disease. For management of acute respiratory failure after an
inﬂuenza infection, NPPV therapy has a high failure rate;
therefore, its use is not recommended for such patients, with
the exception of mild cases.
Recommendation rating of NPPV for CQ10:
1) The use of NPPV in patients with ARDS should be con-
ducted with caution. [Level I evidence, Grade C1
recommendation]
2) NPPV therapy is recommended for management of
patients with milder forms of ARDS and minor damage to
other organs. [Level II evidence, Grade B recommendation]
Recommendation rating of NPPV for CQ11:
1) The use of NPPV is recommended for management of
severe pneumonia in patients with COPD. [Level II evi-
dence, Grade B recommendation]
2) It remains unclear whether NPPV is useful for manage-
ment of severe pneumonia in patients without COPD.
[Level IV evidence, Grade C2 recommendation]
3) Except for mild cases, NPPV is not recommended for
management of severe pneumonia following an inﬂuenza
infection. [Level IV evidence, Grade C2 recommendation]
11. Use in patients in the terminal phase of a disease,
patients with do-not-intubate (DNI) orders, patients with
malignant tumor, and elderly patients
CQ12 Is NPPV useful in patients with a DNI order or elderly
patients with acute respiratory failure?
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respiratory failure in patients in the terminal phase of a
disease or with malignant tumor?
Answer: For the clinical management of acute respiratory
failure under such special circumstances as in patients with a
DNI order or in the elderly, NPPV is often used as an
alternative to intubation if administration of oxygen alone
does not stabilize the patient’s condition. Even in such
patients, the use of NPPV is recommended for management
of disorders for which NPPV is highly recommended, such as
COPD, cardiac failure, and complications associated with
these diseases. In addition, the risk of reduced quality of life
(QOL) due to sequelae from NPPV treatment is minimal in
surviving patients. However, only poor evidence exists for the
effectiveness of NPPV for other medical conditions. There-
fore, if respiratory failure does not improve despite use of
NPPV, the aim of treatment should be the alleviation of
dyspnea and prevention of unnecessary pain and suffering.
Similarly, there is only poor evidence that NPPV is effec-
tive for management of acute respiratory failure in patients
with malignant tumor or in the terminal phase of a disease.
However, the use of NPPV as part of palliative care in patients
with end-stage solid cancer has been demonstrated to be
more effective than oxygen therapy alone for the alleviation
of dyspnea. Thus, the use of NPPV may also be warranted
based on the patient’s right to self-determination of
medical care.
Recommendation rating of NPPV for CQ12:
1) NPPV is recommended for management of acute respira-
tory failure in DNI and elderly patients with COPD or
cardiac failure. [Level of evidence IV, Grade B
recommendation]
2) There is only poor evidence for the effectiveness of NPPV
for management of acute respiratory failure in DNI and
elderly patients without COPD or cardiac failure. If no
improvement is observed, the aim of treatment should be
alleviation of dyspnea. [Level of evidence IV, Grade C1
recommendation]
Recommendation rating of NPPV for CQ13: NPPV can be
used as palliative treatment for respiratory failure in patients
in the terminal phase of a disease or with malignant tumor.
[Level II evidence, Grade C1 recommendation]
12. Use in children
CQ14 Is NPPV useful for management of children with
acute respiratory failure?
CQ15 How can the appropriate indications for the use of
NPPV in children with acute respiratory failure and the
effectiveness of such treatments be determined?
Answer: Only a few studies have evaluated the effective-
ness of NPPV in children with acute medical conditions,
including three small-scale randomized controlled trials that
evaluated patient outcomes. However, the ﬁndings from
these studies suggest that the use of NPPV for management
of viral pneumonia and lower respiratory tract infectionreduces the requirement for intubation, provides short-term
improvement of symptoms, and helps stabilize vital signs.
Therefore, NPPV is recommended for management of chil-
dren with these medical conditions. Evidence also suggests
that NPPV therapy may also provide short-term improvement
of acute asthma symptoms and stabilize vital signs, and may
therefore also be considered in such cases. Findings on the
effectiveness of NPPV for management of other medical
conditions are limited to case reports and series. However,
NPPV may help reduce the rates of intubation and mortality
in patients with respiratory failure after extubation, in
patients with cardiogenic pulmonary edema, and immuno-
compromised patients with respiratory failure. Therefore,
NPPV may be a suitable treatment option in these patients,
depending on the clinical judgment for each individual case.
Based on the reported use of NPPV in randomized con-
trolled trials and the efﬁcacy of treatment, bilevel PAP may be
used as basic NPPV mode, using initial settings of IPAP: 10 cm
H2O, and EPAP: 5 cm H2O. The effectiveness of NPPV treat-
ment should be comprehensively evaluated within 1 h of the
initiation, based on clinical ﬁndings, vital signs, and blood gas
analysis.
Recommendation rating of NPPV for CQ14:
1) The use of NPPV is recommended in children with acute
viral lower respiratory tract infection and pneumonia.
[Level II evidence, Grade B recommendation]
2) The use of NPPV may be considered in children with
asthmatic attacks. [Level II evidence, Grade C1 recom-
mendation]
3) Although the effectiveness of NPPV in children with acute
respiratory failure due to other reasons than those
described above has not yet been established, NPPV ther-
apy may be used depending on the clinical judgment of
each individual case. [Level IV evidence, Grade C2 reco-
mmendation]
Recommendation rating of NPPV for CQ15:
1) Bilevel PAP may be used as the basic NPPV mode with
initial settings of IPAP: 10 cm H2O, and EPAP: 5 cm H2O.
[Level II evidence, Grade C1 recommendation]
2) The initial response to NPPV should be comprehensively
evaluated within 1 h of NPPV initiation, based on clinical
ﬁndings, vital signs, and blood gas analysis. [Level II
evidence, Grade C2 recommendation]
Speciﬁc interventions B: Chronic respiratory failure
1. Restrictive thoracic disease
CQ16 Should long-term NPPV be used for management of
chronic respiratory failure due to restrictive thoracic disease?
Answer: Cohort studies, including relatively large-scale
retrospective studies conducted in the United States, Europe,
and Japan provided evidence for the effectiveness of long-
term NPPV for management of chronic type II respiratory
failure due to restrictive thoracic disease (RTD), such as
pulmonary tuberculosis sequelae and kyphoscoliosis. In all
studies, NPPV improved patient prognosis and QOL. NPPV is
((
(
(
(
(
r e s p i r a t o r y i n v e s t i g a t i o n 5 5 ( 2 0 1 7 ) 8 3 – 9 2 91widely used, with favorable treatment outcomes. Therefore,
ethical considerations prevent randomized controlled stu-
dies. We strongly recommend initiation of long-term NPPV
therapy for indicated patients with RTD.
Recommendation rating of NPPV for CQ16: Long-term
NPPV should be implemented in patients with RTD in whom
the use of NPPV is indicated. [Level IV evidence, Grade A
recommendation]
2. COPD (chronic stage)
CQ17 Should long-term NPPV be used in patients with
chronic respiratory failure due to COPD?
Answer: Evidence suggests that long-term NPPV for treat-
ment of chronic type II respiratory failure due to COPD may
improve survival rates, provide respiratory muscle rest, and
reset the respiratory control system. Moreover, NPPV
improves sleep-disordered breathing in patients with COPD.
Therefore, NPPV improves health-related QOL and reduces
the frequency of rehospitalization and exacerbation. How-
ever, there are a limited number of randomized controlled
trials and cohort studies that suggest the usefulness of NPPV;
thus, its effectiveness has not yet been conclusively demon-
strated in patients with these medical conditions. Therefore,
comprehensive medical treatments should ideally be con-
ducted before deciding whether to implement NPPV therapy.
Furthermore, blood gas measurements, respiratory status
during sleep, QOL, and adherence to NPPV should be eval-
uated 3–4 months after initiating NPPV therapy.
Recommendation rating of NPPV for CQ17: NPPV may be
used in patients with COPD in whom NPPV is indicated. [Level
I evidence, Grade C1 recommendation]
3. Cheyne–Stokes respiration (CSR) in chronic heart fail-
ure (CHF)
CQ18 Should NPPV be used in patients with CSR in CHF?
Which type of equipment should be selected?
Answer: CHF patients with CSR have poor prognosis. In
randomized controlled trials involving patients with CSR,
NPPV therapy was not associated with improved long-term
mortality rates. However, short-term randomized controlled
trials showed that therapies that suppressed CSR improved
cardiac function. Because CSR is caused by CHF in these
patients, treatments for CHF per se should be optimized as a
ﬁrst-line treatment, followed by treatments speciﬁcally tar-
geted for CSR such as CPAP. If CPAP cannot sufﬁciently
suppress the apnea hypopnea index (AHI), or if CPAP is not
well tolerated by the patient, bilevel PAP or ASV should be
considered. If positive pressure ventilation is not effective or is
not tolerated, oxygen inhalation therapy should be considered.
Recommendation rating of NPPV for CQ18:
1) For CHF patients with CSR, CPAP should be ﬁrst conducted
if indicated. [Level I evidence, Grade B recommendation]
2) If CPAP therapy is not sufﬁciently effective, ASV should be
implemented. [Level II evidence, Grade B recommendation]
3) If CPAP therapy is not sufﬁciently effective, bilevel PAP
should be implemented. [Level III evidence, Grade C1
recommendation]4) If positive pressure ventilation is not effective or is not
tolerated, oxygen inhalation therapy should be considered.
[Level II evidence, Grade C1 recommendation]
4. Obesity-hypoventilation syndrome
CQ19 Should either CPAP or bilevel PAP be used as a ﬁrst-
line treatment in patients with obesity-hypoventilation
syndrome?
Answer: Obesity-hypoventilation syndrome is common in
patients with severe obstructive sleep apnea syndrome
(OSAS) (AHIZ30) associated with severe obesity (body mass
index (BMI)Z30 kg/m2) and hypercapnia (PaCO2Z45 mmHg);
these patients have poor prognosis due to severely impaired
gas exchange, and the condition is therefore often associated
with circulatory system-related complications. The results of
a prospective cohort study suggest that CPAP alone may be
effective for treatment, and a randomized controlled trial
reported that the therapeutic effect of bilevel PAP was not
superior to that of CPAP. Therefore, nasal CPAP, together with
a reduction of body weight, is considered the ﬁrst-line
treatment for management of patients with obesity-
hypoventilation syndrome. However, because many of these
patients require higher CPAP pressure than typical OSAS
patients, treatment may be difﬁcult to continue due to
discomfort experienced at higher pressures. If hypopnea
and desaturation during sleep cannot be corrected with CPAP
alone, treatment with bilevel PAP is required.
Recommendation rating of NPPV for CQ19:
1) CPAP should be used as a ﬁrst-line treatment in patients
with obesity-hypoventilation syndrome. [Level III evi-
dence, Grade B recommendation]
2) If CPAP therapy is not sufﬁciently effective, bilevel PAP
should be initiated. [Level III evidence, Grade C1
recommendation]
5. Neuromuscular disease
CQ20 Should NPPV be used for respiratory management of
patients with chronic respiratory failure due to neuromuscu-
lar disease?
Answer: In recent years, various international guidelines
have recommended NPPV as ﬁrst-line treatment for ventila-
tory support for patients with neuromuscular disease. The
evidence suggests that use of NPPV and a cough-assist device
for management of various neuromuscular diseases (e.g.,
Duchenne muscular dystrophy) lowers the risk of asphyxia
and tracheotomy, and improves patient prognosis and QOL.
NPPV therapy may be administered during sleep as well as
during waking hours throughout the day. If a signiﬁcant
decline in pharyngeal and laryngeal function is observed,
and it is difﬁcult to maintain airway clearance despite the use
of a cough-assist device, NPPV therapy with use of a cough-
assist device may only have limited positive effects on
patient prognosis.
Recommendation rating of NPPV for CQ20:
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with chronic respiratory failure due to neuromuscular
disease. [Level II evidence, Grade B recommendation]
2) NPPV should not be used if there is a signiﬁcant decline in
pharyngeal and laryngeal function and it is difﬁcult to
maintain airway clearance. [Level II evidence, Grade D
recommendation]
6. Use in children
CQ21 Should NPPV be used for management of chronic
respiratory disease in children?
CQ22 What should be considered regarding the interface
used for NPPV in infants with respiratory impairment?
Answer: Diseases for which long-term NPPV is indicated in
children include neuromuscular disease, obstructive sleep
apnea, craniofacial malformation, cystic ﬁbrosis, congenital
central hypoventilation syndrome, and scoliosis. The results
of cohort studies suggest that NPPV is particularly effective in
children with neuromuscular disease, resulting in improved
hypoventilation and sleep-disordered breathing, alleviation
of subjective symptoms, reduced hospitalization frequency,
and maintenance of QOL. International guidelines consider
NPPV the ﬁrst-line treatment in children with respiratory
failure due to neurological disease. However, in children with
conditions for which only limited information concerning the
efﬁcacy of NPPV is available, and in children with chronic
respiratory failure and an unknown primary disease, caution
is required when determining the suitability of NPPV therapy.
Moreover, the care system for children in Japan who require
long-term NPPV and may experience exacerbations remains
insufﬁcient.
Although there are only a few NPPV interface types
available for infants, it is desirable to use different types of
masks to prevent skin injury or facial deformations caused by
compression of the mask and to prevent growth defects.
Recommendation rating of NPPV for CQ21:
1) NPPV is effective for management of chronic respiratory
disease in children with neuromuscular disease. [Level IV
evidence, Grade C1 recommendation]
2) NPPV should be indicated with caution in children with
chronic respiratory disease with causes other than
neuromuscular disease. [Level V evidence, Grade C1
recommendation]
CQ22 recommendation: In infants, different types of inter-
faces should be used to prevent facial deformations. [Level V
evidence, Grade C1 recommendation]
7. Rehabilitation
CQ23 Does NPPV provide effective ventilatory support
during exercise?
CQ24 Is it useful to combine exercise rehabilitation with
NPPV during sleep?Answer: Two areas of NPPV for pulmonary rehabilitation
have been studied: (1) ventilatory support during exercise,
and (2) the combined use of NPPV during sleep to provide
respiratory muscle rest and exercise rehabilitation during
the day.
The use of NPPV to provide ventilatory support during
exercise enables patients with severely impaired respiratory
function to conduct highly intensive training for longer time
intervals. This treatment method is particularly effective in
patients with severe COPD who undergo 4 to 8-week exercise
training regimens.
The results of a few randomized controlled trials have
clearly demonstrated that combining exercise rehabilitation
during the day with NPPV therapy during sleep to rest
respiratory muscles improves exercise tolerance. However,
most trial participants had hypercapnia and were indicated
for long-term NPPV or were candidates for this condition.
Therefore, future studies are needed to examine whether this
treatment is also indicated in mild cases of respiratory
impairment.
Recommendation rating of NPPV for CQ23: The use of
NPPV during exercise increases exercise duration and inten-
sity, particularly in patients with severe impairment of
pulmonary function. [Level II evidence, Grade B
recommendation]
Recommendation rating of NPPV for CQ24: Combining
exercise rehabilitation with the use of NPPV during sleep is
effective for improving exercise tolerance in patients with
severely impaired pulmonary function. [Level II evidence,
Grade B recommendation]
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